- In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation
- Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years
- Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide
- For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals
- Lexaria’s anticipated mid-year IND filing would be an important milestone for the company, providing additional interaction with the pharmaceutical industry
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has released its new corporate presentation (https://ir.lexariabioscience.com/presentations). The presentation augments the positive outlook for the coming year put forth in an earlier released shareholder update letter from the company’s CEO, Chris Bunka.
Bunka starts the letter with, “As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people – are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control, such as applied R&D designed to entice others to work with us commercially.”
The letter (https://ibn.fm/Yn6uH) shares that despite the some challenging conditions of 2022, Lexaria is forging ahead. It has not terminated staff but is experiencing the opposite, growing its external headcount to numbers higher than it has been in the past. This has allowed the company to conduct and analyze an unprecedented volume of work. Lexaria has managed to grow while exercising excellent fiscal controls, hitting annual budgets +/- 2% for the last two years. Lexaria plans for further growth in 2023 with its patented DehydraTECH(TM) technology.
DehydraTECH is a disruptive drug delivery technology that is more effective at delivering active pharmaceutical ingredients (“APIs”) into the bloodstream and brain tissue. It is applied to multiple ingestible product formats, including tablets, capsules, oral suspensions, mouth melts, and more.
The company has already seen 28 patents granted and roughly 50 patent applications pending worldwide for its DehydraTECH technology (https://ibn.fm/TB2sL). Pharmacokinetic studies have shown the delivery of higher API quantities in less time, including cannabidiol (“CBD”) for hypertension, oral nicotine for reduced risk, and antiviral drugs for COVID-19 and other infectious diseases. An Investigational New Drug (“IND”) enabling program is currently underway for DehydraTECH-CBD as a prospective registered treatment for hypertension with the U.S. Food and Drug Administration (“FDA”).
Pushing forward in 2023, Lexaria’s DehydraTECH drug delivery platform has multiple mainstream applications in cannabinoids, oral nicotine, antivirals, phosphodiesterase inhibitors, and other APIs. This technology increases bioavailability, improves the speed of onset, reduces drug administration costs, and masks unwanted tastes. The company’s pipeline addresses serious unmet patient needs with substantial market potential.
For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals. Additionally, during 2023, Lexaria expects to both submit its IND file and commence its IND clinical study – a major step in its maturation as a pharmaceutical company and will be the primary research focus once it begins.
Lexaria believes that if the IND hypertension program is a success, it could potentially pave the way for more commercial pursuits of DehydraTECH-CBD for therapeutic use. This would be a real milestone for the company as an additional way to interact with the pharmaceutical industry.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com